NCT00444535 2021-10-25
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis
Phase 2 Completed
Clinical Trials
34 trialsNCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00320411 2019-01-31
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00477464 2018-09-17
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT00111787 2017-05-31
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT00089999 2017-02-28
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00524303 2016-11-11
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
GlaxoSmithKline
Phase 2 Completed
NCT00422903 2016-05-12
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01068704 2015-10-12
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00105950 2015-09-28
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00387127 2015-06-25
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00062686 2015-04-15
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01138046 2014-10-07
Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC
GlaxoSmithKline
Phase 2 Completed
NCT00356811 2014-07-21
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT00044343 2014-07-10
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
GlaxoSmithKline
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT00558103 2013-02-04
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01128543 2012-12-12
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
Phase 2 Completed
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00820924 2012-03-28
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
GlaxoSmithKline
Phase 2 Terminated
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00371566 2010-04-06
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed